276
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

A phase-1 trial of linsitinib (OSI-906) in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma

, , , , , , , , , , & show all
Pages 1721-1729 | Received 22 Oct 2020, Accepted 08 Jan 2021, Published online: 28 Jan 2021
 

Abstract

We report results of a phase-1 study evaluating the safety and anti-cancer activity of the small molecule insulin-like growth factor-1 receptor (IGF-1R) inhibitor, linsitinib combined with bortezomib, and dexamethasone in relapsed/refractory multiple myeloma. Nineteen patients were enrolled across four dose-escalation cohorts (75–150 mg bid). The maximum tolerated dose of linsitinib was 125 mg. The most frequent Grade 3/4 AEs occurring in ≥10% of patients were thrombocytopenia (53%), bone pain (26%), neutropenia (21%), diarrhea (14%), anemia (14%), rash (10%), and lung infection (10%). Study discontinuation due to treatment-related AEs was low (16%). Across all cohorts the ORR was 61% (95% CI: 28.9–75.6%). Three partial response or greater and one stable disease were observed in proteasome inhibitor (PI) refractory patients (n = 5). Median PFS was 7.1 months (95% CI: 3.6–NA). Linsitinib plus bortezomib and dexamethasone demonstrate a manageable safety profile while the clinical benefit particularly in PI refractory patients warrants further exploration.

Acknowledgements

EG is supported by the MMRC. This material was presented in part at the annual meetings of the American Society of Hematology 2015 and the International Myeloma Workshop 2015. We are grateful to the patients who participated in this study, the investigators and coordinators at the clinical sites, and the employees of Astellas Margaret Singh and MMRC including Daniel Auclair and Joan Levy.

Author contributions

SK contributed to data analysis and wrote the manuscript; DW, MG, RL, JK, AJ, EG HP, ZL data acquisition, data analysis and interpretation; LEL and AL contributed to the statistical design and analysis; ST designed the study, contributed to the acquisition of data, data analysis and interpretation; All authors were involved at each stage of manuscript preparation and approved the final version.

Disclosure statement

Honoria-BMS, Janssen, Takeda, Amgen, Sanofi, Karyopharm; Consultant-GlaxoSmithKine, BMS, Amgen Canada, Grants-Amgen, BMS, Pfizer, Genentech, GlaxoSmithKline, Janssen.

Additional information

Funding

This work was supported by Astellas and the Multiple Myeloma Research Consortium (MMRC).

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.